相关实验视频
Updated: Jul 17, 2026

08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
血小板糖蛋白IIb/IIIa对抗剂. 血小板糖蛋白IIb/IIIa对抗剂. 血小板糖蛋白IIb/IIIa对抗剂. 关于它们的药理学和临床使用的相关问题是什么?
R M Scarborough1, N S Kleiman, D R Phillips
1COR Therapeutics, Inc, South San Francisco, CA, USA. scarborough@corr.com
Circulation
|July 27, 1999
概括
血小板糖蛋白 (GP) IIb/IIIa对抗剂对于治疗急性冠状动脉综合征至关重要. 需要进一步的研究来优化它们的药理学和临床使用,以获得更好的患者结果.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 血小板糖蛋白 (GP) IIb/IIIa复合体是抑制血栓形成的关键标.
- GP IIb/IIIa对抗剂在治疗急性冠状动脉综合征方面表现有前途.
研究的目的:
- 审查有关GP IIb/IIIa对抗剂的未解决问题.
- 探索它们的药理学,临床有用性和未来的治疗潜力.
主要方法:
- 对GPIIb/IIIa抗剂的现有文献的审查.
- 对药理性质的分析,包括亲和力,可逆性和特异性.
- 讨论临床应用挑战和监测.
主要成果:
- 几种GP IIb/IIIa对抗剂已经证明了临床效用.
- 尚未解决的问题包括受体的可用性,新表皮质诱导的血小板缺血症和监测方法.
- 口服抗剂的治疗指数需要进一步评估.
结论:
- 优化GP IIb/IIIa对抗剂治疗需要解决药理学和临床的不确定性.
- 未来的研究将决定这种药物类别的更广泛的临床应用.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...

